Pharmaceutical compositions of nilotinib
Amorphous solid dispersions of nilotinib fumarate or nilotinib tartrate are provided, as well as pharmaceutical compositions thereof, wherein the compositions exhibit enhanced bioavailability in the fasted state. Preferably, the compositions may be orally administered to a patient in either the fed or fasted state, with a decrease or elimination of the food effect. Preferably, following oral administration of the pharmaceutical compositions, there is no substantial difference in the pharmacokinetic parameters (e.g., C max , AUC 0-t and/or AUC 0-infinity ) of nilotinib, regardless of whether the pharmaceutical compositions are administered to a subject in the fed or fasted state.
1. A pharmaceutical composition comprising a therapeutically effective amount of an amorphous solid dispersion of nilotinib tartrate,
wherein a dosage of nilotinib administered in the pharmaceutical composition is reduced by at least about 50% w/w compared to a dosage of nilotinib administered in a reference formulation.
2. The pharmaceutical composition according to claim 1 , wherein the dosage of nilotinib administered in a unit dosage form of the reference formulation is 150 mg.
3. The pharmaceutical composition according to claim 1 , wherein the dosage of nilotinib administered in a unit dosage form of the reference formulation is 200 mg.
4. The pharmaceutical composition according to claim 1 , wherein the amount of nilotinib in a unit dosage form of the pharmaceutical composition is about 75 mg.
5. The pharmaceutical composition according to claim 1 , wherein the amount of nilotinib in a unit dosage form of the pharmaceutical composition is about 100 mg.
6. The pharmaceutical composition according to claim 1 , wherein the amount of nilotinib in a unit dosage form of said composition is about 71 mg.
7. The pharmaceutical composition according to claim 1 , wherein the amount of nilotinib in a unit dosage form of said composition is about 95 mg.
8. The pharmaceutical composition according to claim 1 , wherein said pharmaceutical composition, after oral administration in a human subject under fasting conditions, provides a geometric mean area under the curve AUC0-t ranging from about 80% to about 125% of a geometric mean area under the curve AUC0-t of said reference formulation following oral administration in a human subject under fasting conditions.
9. The pharmaceutical composition according to claim 1 , wherein said pharmaceutical composition, after oral administration under fasting conditions, is bioequivalent to the reference formulation, after oral administration under fasting conditions.